Table 5.
Non-progressors* |
||||||||
---|---|---|---|---|---|---|---|---|
Percentage in sustained remission | Percentage not in sustained remission | Sensitivity | Specificity | PPV | NPV | p Value | Likelihood ratio (95% CI) | |
DAS28 Cr | 62 | 45 | 0.19 | 0.90 | 0.62 | 0.55 | 0.015 | 1.82 (1.11 to 2.97) |
DAS28-3 Cr | 63 | 45 | 0.16 | 0.91 | 0.63 | 0.53 | 0.022 | 1.77 (1.04 to 3.02) |
Boolean Cr | 62 | 47 | 0.05 | 0.98 | 0.69 | 0.53 | 0.11 | 2.47 (0.77 to 7.91) |
Boolean-3 Cr | 55 | 47 | 0.12 | 0.91 | 0.55 | 0.53 | 0.32 | 1.33 (0.75 to 2.38) |
SDAI Cr | 74 | 47 | 0.08 | 0.97 | 0.74 | 0.53 | 0.025 | 2.96 (1.09 to 8.05) |
SDAI-4 Cr | 60 | 47 | 0.11 | 0.93 | 0.60 | 0.53 | 0.14 | 1.62 (0.8 to 3.09) |
Sensitivity, specificity, PPV (positive predictive value), NPV (negative predictive value) and positive likelihood ratios, all with absence of radiographic progression from baseline to 8 years as outcome.
*Non-progressors—patients without radiographic progression from baseline to 8 years.
DAS28, disease activity score calculated on 28 joints; SDAI Cr, Simplified Disease Activity Index less than 3.3 remission criterion.